Venetoclax is Well Tolerated, Active in Non-Hodgkin Lymphoma

Share this content:
Venetoclax was well-tolerated with variable efficacy against various non-Hodgkin lymphoma subtypes.
Venetoclax was well-tolerated with variable efficacy against various non-Hodgkin lymphoma subtypes.

Venetoclax was well-tolerated with variable efficacy against various non-Hodgkin lymphoma (NHL) subtypes, according results from cohort B of the M12-175 trial (ClinicalTrials.gov Identifier: NCT01328626), a first-in-human study published in the Journal of Clinical Oncology.1

Venetoclax is a highly selective BCL-2 inhibitor; BCL-2 abnormalities are present in follicular lymphoma (FL), diffuse large B-cell lymphomas (DLBCL), and mantle cell lymphoma (MCL). This analysis evaluated the safety, pharmacokinetics, and efficacy of venetoclax in patients with NHL.

Cohort B of the M12-175 trial treated 106 patients with relapsed or refractory NHL with venetoclax once daily until disease progression or unacceptable toxicity (target doses, 200 to 1200 mg).

The NHL subtypes included MCL, FL, DLBCL, DLBCL arising from CLL Richter transformation (DLBCL-RT), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL).

Treatment-emergent adverse events occurred in 97% of patient, most of which were grade 1 to 2 in severity. Grade 3/4 events occurred in 56% of patients, with the most common including anemia, neutropenia, and thrombocytopenia. More common serious adverse events (3% each) were hyponatremia, influenza, and lower respiratory tract infection. A maximum tolerated dose was not reached.

The overall response rate of venetoclax was 44%; the response rate was 75% in MCL, 38% in FL, 18% in DLBCL, 43% in DLBCL-RT, 67% in MZL, and 100% in WM.

The overall median progression-free survival was 6 months, which varied from 14 months among patients with MCL to 11 months in FL and 1 month in DLBCL.

RELATED: Allogeneic HSCT After PD-1 Blockade Appears Feasible in R/R Lymphoma

The investigators determined that 800 mg and 1200 mg of venetoclax are the recommended single-agent dose for MCL and FL or DLBCL, respectively. The mechanism of action of venetoclax suggests it may partner well in combination regimens.

Reference

  1. Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patietns with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017 Jan 17. doi: 10.1200/JCO.2016.70.4320 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters